Rinvoq vs. Olumiant

• Are Rinvoq and Olumiant the Same Thing?
• What Are Possible Side Effects of Rinvoq?
• What Are Possible Side Effects of Olumiant?
• What Is Rinvoq?
• What Is Olumiant?
• What Drugs Interact with Rinvoq?
• What Drugs Interact with Olumiant?
• How Should Rinvoq Be Taken?
• How Should Olumiant Be Taken?

Rinvoq (upadacitinib) and Olumiant (baricitinib) are Janus kinase (JAK) inhibitors indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to either methotrexate (Rinvoq) or a tumor necrosis factor (TNF) antagonist (Olumiant).

Side effects of Rinvoq and Olumiant that are similar include upper respiratory tract infections (common cold, sinus infections) and nausea.

Side effects of Rinvoq that are different from Olumiant include cough and fever.

Side effects of Olumiant that are different from Rinvoq include cold sores (herpes simplex and shingles (herpes zoster).

Both Rinvoq and Olumiant may interact with live vaccines.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Olumiant may also interact with methotrexate, probenecid, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and other drugs to treat rheumatoid arthritis.

Common side effects of Rinvoq include:

• upper respiratory tract infections,
• nausea,
• cough, and
• fever

Side effects of Olumiant nclude<:/p>

• upper respiratory tract infections (common cold, sinus infections),
• nausea,
• cold sores (herpes simplex), and
• shingles (herpes zoster)

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe rheumatoid arthritis (RA) who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist.

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

Olumiant may interact with probenecid. Tell your doctor all medications and supplements you use.

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

The recommended dose of Olumiant is 2 mg once daily.